Your browser is no longer supported. Please, upgrade your browser.
Cabaletta Bio, Inc.
Index- P/E- EPS (ttm)-1.24 Insider Own3.30% Shs Outstand23.26M Perf Week0.17%
Market Cap273.77M Forward P/E- EPS next Y-2.11 Insider Trans-47.18% Shs Float22.80M Perf Month-16.10%
Income-29.40M PEG- EPS next Q-0.36 Inst Own68.60% Short Float7.06% Perf Quarter-16.51%
Sales- P/S- EPS this Y-71.30% Inst Trans-0.11% Short Ratio14.33 Perf Half Y4.80%
Book/sh5.05 P/B2.33 EPS next Y-51.10% ROA-22.40% Target Price20.33 Perf Year-19.32%
Cash/sh5.03 P/C2.34 EPS next 5Y- ROE-23.00% 52W Range5.51 - 17.86 Perf YTD-5.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.55% Beta-
Dividend %- Quick Ratio28.00 Sales past 5Y- Gross Margin- 52W Low102.36% ATR0.86
Employees31 Current Ratio28.00 Sales Q/Q- Oper. Margin- RSI (14)38.21 Volatility6.53% 6.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-75.00% Profit Margin- Rel Volume1.19 Prev Close11.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume112.27K Price11.15
Recom2.00 SMA20-9.47% SMA50-13.85% SMA200-3.85% Volume134,086 Change-5.35%
Jan-08-21Initiated Chardan Capital Markets Buy $21
Oct-13-20Initiated H.C. Wainwright Buy $20
Nov-19-19Initiated Morgan Stanley Overweight $19
Nov-19-19Initiated Evercore ISI Outperform $25
Nov-19-19Initiated Cowen Outperform
Jan-19-21 11:37PM  
Jan-07-21 08:00AM  
Jan-04-21 08:00AM  
Dec-08-20 04:30PM  
Dec-04-20 08:25AM  
Nov-23-20 08:00AM  
Nov-10-20 07:30AM  
Oct-31-20 08:00AM  
Oct-22-20 07:39AM  
Sep-25-20 08:00AM  
Sep-08-20 08:00AM  
Aug-25-20 08:00AM  
Aug-06-20 07:30AM  
Aug-03-20 08:00AM  
Jul-24-20 07:42AM  
Jul-07-20 08:00AM  
Jun-24-20 04:25PM  
Jun-01-20 12:00PM  
May-28-20 08:00AM  
May-27-20 08:00AM  
May-18-20 04:30PM  
May-12-20 07:00AM  
May-06-20 08:00AM  
Apr-17-20 12:00PM  
Mar-30-20 07:00AM  
Feb-20-20 08:00AM  
Jan-30-20 09:26AM  
Jan-29-20 08:00AM  
Dec-23-19 04:32AM  
Nov-26-19 08:00AM  
Oct-25-19 05:10PM  
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
5AM Ventures V, L.P.10% OwnerJan 12Sale13.0085,0001,105,000369,688Jan 12 05:07 PM
5AM Ventures V, L.P.10% OwnerJan 08Sale13.00302,0003,926,000380,218Jan 12 05:07 PM
5AM Ventures V, L.P.10% OwnerDec 10Sale14.75298,0004,395,500417,629Dec 14 05:58 PM